文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

小檗碱剂量依赖性抑制脂多糖诱导的大鼠II型肺泡上皮细胞促凝及纤溶抑制因子表达

[Berberine dose-dependently inhibits the expression of procoagulant and fibrinolytic inhibitory factors in lipopolysaccharide-induced rat type II alveolar epithelial cells].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论体外实验显示小檗碱20-80 μmol/L可剂量依赖性纠正脂多糖诱导的大鼠II型肺泡上皮细胞促凝/纤溶抑制因子异常,80 μmol/L效果最明显。

该研究为体外细胞实验,采用大鼠II型肺泡上皮细胞(RLE-6TN),以5 mg/L脂多糖刺激24小时建立损伤模型,并设小檗碱20、50、80 μmol/L预处理1小时组。结果显示脂多糖组TF、PAI-1蛋白及mRNA表达升高、TFPI降低,上清APC、AT III降低而PIIIP、TAT升高;小檗碱预处理可剂量依赖性纠正上述异常,以80 μmol/L最明显(各项P<0.01)。作者认为小檗碱可能成为ARDS肺泡高凝与纤溶抑制的新治疗靶点。

要点

  • 体外大鼠II型肺泡上皮细胞(RLE-6TN)经5 mg/L脂多糖刺激24小时后,TF、PAI-1蛋白及mRNA表达显著升高,TFPI蛋白及mRNA显著降低。
  • 脂多糖刺激后细胞上清APC、AT III显著降低,PIIIP、TAT显著升高,提示促凝及纤溶抑制表型。
  • 小檗碱20、50、80 μmol/L预处理1小时可剂量依赖性纠正上述异常,以80 μmol/L最明显(各项P<0.01)。
  • 80 μmol/L小檗碱组较脂多糖组TF蛋白0.45±0.02 vs. 0.55±0.03、TF mRNA 0.39±0.08 vs. 1.48±0.11、PAI-1蛋白0.37±0.02 vs. 0.64±0.04、PAI-1 mRNA 1.14±0.29 vs. 4.18±0.44,均P<0.01。
  • 作者认为小檗碱可能是ARDS肺泡高凝和纤溶抑制的新治疗靶点。

适用人群与场景

  • 体外培养的大鼠II型肺泡上皮细胞(RLE-6TN细胞),取对数生长期细胞用于实验。

诊断标准与关键阈值

  • 根据CCK-8法检测的抑制率曲线,小檗碱对RLE-6TN细胞的半数抑制浓度(IC50)为81.16 μmol/L,据此选择20、50、80 μmol/L作为干预浓度。
  • 脂多糖刺激浓度5 mg/L,刺激时间24小时。

处置流程与药物剂量

  • 小檗碱预处理组分别以20、50、80 μmol/L小檗碱预处理1小时,再与5 mg/L脂多糖共培养24小时。
  • 空白对照组用DMEM培养,脂多糖组仅用5 mg/L脂多糖刺激。

研究设计与关键结果

  • 研究类型为体外细胞实验;细胞分组为空白对照组、脂多糖组(5 mg/L)及小檗碱20、50、80 μmol/L预处理组。
  • 与空白对照组比较,脂多糖刺激24小时后RLE-6TN细胞TF、PAI-1蛋白及mRNA表达显著升高,TFPI蛋白及mRNA表达显著降低;上清APC、AT III显著降低,PIIIP、TAT显著升高。
  • 与脂多糖组比较,小檗碱80 μmol/L组TF蛋白(TF/GAPDH)0.45±0.02 vs. 0.55±0.03、TF mRNA(2-ΔΔCt)0.39±0.08 vs. 1.48±0.11、PAI-1蛋白(PAI-1/GAPDH)0.37±0.02 vs. 0.64±0.04、PAI-1 mRNA(2-ΔΔCt)1.14±0.29 vs. 4.18±0.44,均P<0.01。
  • 与脂多糖组比较,小檗碱80 μmol/L组TFPI蛋白(TFPI/GAPDH)0.53±0.02 vs. 0.45±0.02、TFPI mRNA(2-ΔΔCt)0.94±0.08 vs. 0.40±0.05,均P<0.01。
  • 与脂多糖组比较,小檗碱80 μmol/L组上清APC 1 358.5±26.0 μg/L vs. 994.2±23.1 μg/L、AT III 118.0±7.4 μg/L vs. 84.4±2.7 μg/L,均P<0.01;PIIIP 11.2±0.4 μg/L vs. 18.6±0.9 μg/L、TAT 222.1±2.8 ng/L vs. 287.6±7.0 ng/L,均P<0.01。
  • 小檗碱对上述指标的纠正作用呈剂量依赖性,以80 μmol/L组最明显。

证据类型、等级与局限

  • 证据类型:体外细胞实验(大鼠II型肺泡上皮细胞RLE-6TN)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为小檗碱可能成为ARDS肺泡高凝和纤溶抑制的新治疗靶点。
  • 本文为体外细胞实验,结果尚不能直接转化为急诊/ICU临床用药推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effects of berberine on procoagulant and fibrinolytic inhibitory factors produced by rat type II alveolar epithelial cell (AEC II) induced by lipopolysaccharide (LPS).

METHODS: AEC II cells (RLE-6TN cells) were cultured in vitro, and the cells in logarithmic growth phase were collected. The cytotoxicity text of berberine was detected by cell counting kit-8 (CCK-8) to determine the drug concentration range according to inhibition concentration of half cells (IC50). The RLE-6TN cells were divided into five groups, the cells in blank control group were cultured in DMEM; the cells in LPS group were stimulated with 5 mg/L LPS; and the cells in berberine pretreatment groups were pretreated with 20, 50 and 80 μmol/L berberine for 1 hour, and then were co-cultured with 5 mg/L LPS. The cells were collected after LPS induced for 24 hours. The protein and mRNA expression levels of tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasminogen activator inhibitor-1 (PAI-1) in the cells were detected by Western blotting and real-time fluorescence quantification reverse transcription-polymerase chain reaction (RT-qPCR). The levels of activated protein C (APC), precollagen III peptide (PIIIP), thrombin-antithrombin complex (TAT) and antithrombin III (AT III) in the cell supernatant were measured by enzyme linked immunosorbent assay (ELISA).

RESULTS: According to the inhibition rate curve, the IC50 of berberine on RLE-6TN cells was 81.16 μmol/L. Therefore, 20, 50 and 80 μmol/L were selected as the intervention concentration of berberine. Compared with the blank control group, the expression and secretion of procoagulant and fibrinolytic inhibitory factors were abnormal in RLE-6TN cells after LPS induced for 24 hours. The protein and mRNA expression levels of TF and PAI-1 in the LPS group were significantly increased, but the protein and mRNA expression levels of TFPI were significantly decreased. Meanwhile, the levels of APC and AT III in the cell supernatant were significantly decreased, while the levels of PIIIP and TAT were significantly increased. After pretreatment with berberine, the abnormal expression and secretion of procoagulant and fibrinolytic inhibitory factors induced by LPS were corrected in a dose-dependent manner, especially in 80 μmol/L. Compared with the LPS group, the protein and mRNA expression levels of TF and PAI-1 in the berberine 80 μmol/L group were significantly decreased [TF protein (TF/GAPDH): 0.45±0.02 vs. 0.55±0.03, TF mRNA (2-ΔΔCt): 0.39±0.08 vs. 1.48±0.11, PAI-1 protein (PAI-1/GAPDH): 0.37±0.02 vs. 0.64±0.04, PAI-1 mRNA (2-ΔΔCt): 1.14±0.29 vs. 4.18±0.44, all P < 0.01] and those of TFPI were significantly increased [TFPI protein (TFPI/GAPDH): 0.53±0.02 vs. 0.45±0.02, TFPI mRNA (2-ΔΔCt): 0.94±0.08 vs. 0.40±0.05, both P < 0.01]. Meanwhile, the levels of APC and AT III in the cell supernatant were significantly increased [APC (μg/L): 1 358.5±26.0 vs. 994.2±23.1, AT III (μg/L): 118.0±7.4 vs. 84.4±2.7, both P < 0.01], while those of PIIIP and TAT were significantly decreased [PIIIP (μg/L): 11.2±0.4 vs. 18.6±0.9, TAT (ng/L): 222.1±2.8 vs. 287.6±7.0, both P < 0.01].

CONCLUSIONS: Berberine could inhibit the LPS-induced expressions of procoagulant and fibrinolytic inhibitory factors in rat AEC II cells and promote the expressions of anticoagulant factors in a dose-dependent manner. Berberine may be a new therapeutic target for alveolar hypercoagulability and fibrinolysis inhibition in acute respiratory distress syndrome (ARDS).

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li X, Yang G, Shen F, et al. [Berberine dose-dependently inhibits the expression of procoagulant and fibrinolytic inhibitory factors in lipopolysaccharide-induced rat type II alveolar epithelial cells]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 33565401. doi:10.3760/cma.j.cn121430-20200917-00636

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。